|Mr. Sheldon L. Koenig||President, CEO & Director||1.2M||N/A||1966|
|Mr. Benjamin O. Looker||General Counsel||550.35k||N/A||1982|
|Dr. JoAnne Micale Foody FACC, M.D.||Chief Medical Officer||771.19k||N/A||1966|
|Mr. Benjamin Halladay M.B.A.||Chief Financial Officer||N/A||N/A||1986|
|Mr. Glenn P. Brame||Chief Technical Operations Officer||N/A||N/A||1958|
|Tiffany Aldrich M.B.A.||Associate Director of Corporate Communications||N/A||N/A||N/A|
|Ms. Betty Jean Swartz||Chief Business Officer||N/A||N/A||N/A|
|Mr. Eric J. Warren R.Ph.||Chief Commercial Officer||N/A||N/A||1972|
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 9.